Article Figures & Data
Figures
- Figure 1.
(A) Effect of MTX monotherapy, ETN monotherapy, and MTX+ETN combination therapy on the percentage of patients achieving ACR20, MDA, VLDA at week 24 by sex, and (B) mean change in PASDAS from baseline to week 24 by sex. N = no. of patients in the full analysis set. Descriptive statistics were used to examine outcomes within each treatment arm. P values were estimated from the normal approximation and are nominal; only P values ≤ 0.05 are shown. ACR: American College of Rheumatology; ETN: etanercept; MDA: minimal disease activity; MTX: methotrexate ; PASDAS: Psoriatic Arthritis Disease Activity Score; SE: standard error; VLDA: very low disease activity.
- Figure 2.
Effect of MTX monotherapy, ETN monotherapy, and MTX+ETN combination therapy on MDA and PASDAS at week 24 by sex (modeling analyses). (A) Least squares estimate MDA at week 24. (B) Least squares estimate change in PASDAS from baseline to week 24. N = no. of patients in the full analysis set. The mean differences between BMI categories were estimated from the normal approximation. For MDA, treatment differences and P values for comparison with MTX monotherapy were based on logistic model adjusted for prior nonbiologic DMARD use, baseline BMI status (kg/m2; ≤ 30 or > 30), gender, and treatment*gender interaction term. For PASDAS change, treatment differences and P values for comparison with MTX monotherapy were based on ANCOVA model adjusted for prior nonbiologic DMARD use, baseline BMI status (≤ 30 or > 30), and treatment*gender interaction term. P values are for the treatment difference in ETN arms to MTX monotherapy for the difference of male vs female and are nominal with no adjustments for multiplicity. DMARD: disease-modifying antirheumatic drug; ETN: etanercept; MDA: minimal disease activity; MTX: methotrexate; PASDAS: Psoriatic Arthritis Disease Activity Score; SE: standard error.
- Figure 3.
Effect of MTX monotherapy, ETN monotherapy, and MTX+ETN combination therapy on ACR20, MDA, VLDA, PASDAS, and BSA at week 24 by BMI category (descriptive statistics). (A) Percentage of patients achieving ACR20, MDA, and VLDA at week 24. (B) Mean change in PASDAS from baseline to week 24. (C) Mean percentage of BSA improvement from baseline to week 24 in patients with baseline BSA ≥ 3%. (D) Mean percentage of BSA improvement from baseline to week 24 in patients with baseline BSA ≥ 10%. N = no. of patients in the full analysis set. Descriptive statistics were used to examine outcomes within each treatment arm. P values were estimated from the normal approximation and are nominal; only P values ≤ 0.05 are shown. ACR: American College of Rheumatology; BSA: body surface area; ETN: etanercept; MDA: minimal disease activity; MTX: methotrexate; PASDAS: Psoriatic Arthritis Disease Activity Score; SE: standard error; VLDA: very low disease activity.
- Figure 4.
Effect of MTX monotherapy, ETN monotherapy, and MTX+ETN combination therapy on sPGA score at week 24 by BMI category (descriptive statistics for baseline BSA ≥ 3% and modeling analyses for baseline BSA ≥ 10%). (A) Achieving an sPGA score of clear (0) or almost clear (1) at week 24 in patients with baseline BSA ≥ 3%. (B) Achieving an sPGA score of clear (0) or almost clear (1) at week 24 in patients with baseline BSA ≥ 10%. N = no. of patients in the full analysis set with BSA ≥ 3% or ≥ 10% at baseline. The mean differences between BMI categories were estimated from the normal approximation. Treatment differences and P values for comparison with MTX monotherapy were based on logistic model adjusted for prior nonbiologic DMARD use, baseline BMI status (kg/m2; ≤ 30 or > 30) and treatment*BMI status interaction term. P values are for the treatment difference in ETN arms to MTX monotherapy for the difference of BMI ≤ 30 vs > 30 and are nominal with no adjustments for multiplicity. BSA: body surface area; DMARD: disease-modifying antirheumatic drug; ETN: etanercept; MTX: methotrexate; SE: standard error; sPGA: static physician global assessment.
Tables
MTX Monotherapy, N = 284 ETN Monotherapy, N = 284 MTX+ETN Combination Therapy, N = 283 Male Female P, Male vs Femalea,b Male Female P, Male vs Femalea,b Male Female P, Male vs Femalea,b PsA duration, yrs 3.8 (0.7) 3.6 (0.6) – 3.8 (0.6) 2.3 (0.5) – 3.1 (0.5) 2.8 (0.6) – SJC66 14.1 (1.1) 12.0 (0.6) – 11.7 (0.8) 11.3 (0.8) – 9.8 (0.6) 12.7 (0.9) 0.008 TJC68 20.4 (1.5) 21.3 (1.1) – 18.4 (1.2) 19.4 (1.3) – 17.4 (1.1) 22.7 (1.4) 0.004 PGA, 0–100 57.0 (1.8) 59.8 (1.5) – 57.5 (1.6) 59.3 (1.4) – 56.1 (1.4) 59.9 (1.6) – CRP, mg/L 10.9 (1.5) 10.2 (1.2) – 11.3 (1.4) 10.1 (1.1) – 7.8 (0.8) 9.6 (1.2) – SPARCC enthesitis 3.2 (0.4) 4.4 (0.4) 0.03 3.4 (0.3) 4.0 (0.4) – 3.5 (0.3) 4.8 (0.4) 0.02 sPGA 2.6 (0.1) 2.6 (0.1) – 2.7 (0.1) 2.5 (0.1) – 2.6 (0.1) 2.4 (0.1) – sPGA status, n (%) < 2 22 (7.7) 26 (9.2) – 16 (5.6) 24 (8.5) – 22 (7.8) 30 (10.6) – ≥ 2 101 (35.6) 132 (46.5) – 135 (47.5) 109 (38.4) – 122 (43.1) 109 (38.5) – BSA, % 14.4 (1.8) 11.3 (1.4) 0.04 12.0 (1.3) 9.4 (1.2) – 11.6 (1.4) 9.8 (1.2) – BSA < 3%, n (%) 40 (14.1) 52 (18.3) – 51 (18.0) 54 (19.0) – 51 (18.0) 55 (19.4) – ≥ 3%, n (%) 84 (29.6) 108 (38.0) – 100 (35.2) 79 (27.8) – 93 (32.9) 84 (29.7) – HAQ-DI 1.1 (0.1) 1.4 (0.1) < 0.0001 1.0 (0.1) 1.3 (0.1) 0.0001 1.0 (0.1) 1.3 (0.1) < 0.0001 PtGA, 0–100 57.3 (2.0) 63.3 (1.8) 0.02 61.9 (1.9) 64.1 (1.8) – 57.9 (1.7) 64.1 (1.8) 0.01 PtGAJP, 0–100 53.6 (1.8) 58.0 (1.8) – 53.9 (1.9) 59.4 (1.8) 0.04 51.9 (1.7) 59.5 (1.9) 0.003 SF-36 PCS 36.9 (0.8) 34.6 (0.6) 0.02 38.4 (0.7) 37.2 (0.7) – 39.5 (0.8) 35.2 (0.8) 0.0001 SF-36 MCS 47.1 (1.1) 43.7 (1.00) 0.02 46.2 (1.0) 43.9 (1.1) – 47.7 (0.9) 44.8 (1.0) 0.03 Values are expressed as mean (SE) unless otherwise stated.
↵aP values are nominal.
↵bOnly P values ≤ 0.05 are shown. BSA: body surface area; CRP: C-reactive protein; ETN: etanercept; HAQ-DI: Health Assessment Questionnaire-Disability Index; MTX: methotrexate; MCS: Mental Component Summary; PCS: Physical Component Summary ; PGA: physician global assessment; PsA: psoriatic arthritis; PtGA: patient global assessment of disease activity; PtGAJP: patient global assessment of joint pain; SE: standard error; SF-36: 36-item Short Form Health Survey; SJC66: swollen joint count in 66 joints; SPARCC: Spondyloarthritis Research Consortium of Canada; sPGA: static physician global assessment (of psoriasis); TJC68: tender joint count in 68 joints.
MTX Monotherapy, N = 284 ETN Monotherapy, N = 284 MTX+ETN Combination Therapy, N = 283 BMI, ≤ 30 BMI, > 30 Pa,b, BMI ≤ 30 vs > 30 BMI, ≤ 30 BMI, > 30 Pa,b, BMI ≤ 30 vs > 30 BMI, ≤ 30 BMI, > 30 Pa,b, BMI ≤ 30 vs > 30 PsA duration, yrs 3.9 (0.6) 3.4 (0.6) – 2.8 (0.4) 3.5 (0.7) – 3.9 (0.6) 1.9 (0.4) 0.01 SJC66 11.1 (0.7) 14.9 (0.9) 0.001 11.2 (0.7) 11.9 (1.0) – 10.1 (0.6) 12.7 (1.0) 0.02 TJC68 18.4 (1.2) 23.6 (1.3) 0.003 17.3 (1.1) 20.7 (1.3) – 18.0 (1.1) 22.6 (1.5) 0.01 PGA, 0–100 57.1 (1.6) 60.2 (1.7) – 58.2 (1.5) 58.7 (1.6) – 56.6 (1.4) 59.8 (1.6) – CRP, mg/L 9.6 (1.4) 11.5 (1.3) – 10.5 (1.5) 11.1 (1.1) – 8.0 (1.0) 9.6 (0.9) – SPARCC enthesitis 3.3 (0.3) 4.4 (0.4) 0.03 3.6 (0.3) 3.8 (0.4) – 3.6 (0.3) 4.8 (0.4) 0.04 sPGA 2.5 (0.1) 2.7 (0.1) – 2.5 (0.1) 2.8 (0.1) 0.02 2.5 (0.1) 2.5 (0.1) – sPGA status < 2, n (%) 24 (8.5) 24 (8.5) 25 (8.8) 15 (5.3) 27 (9.5) 25 (8.8) ≥ 2, n (%) 120 (42.3) 113 (39.8) – 128 (45.1) 116 (40.8) – 133 (47.0) 98 (34.6) – BSA, % 12.3 (1.5) 13.1 (1.7) – 10.9 (1.2) 10.4 (1.2) – 10.2 (1.1) 11.5 (1.6) – BSA < 3%, n (%) 42 (14.8) 50 (17.6) – 58 (20.4) 47 (16.5) – 62 (21.9) 44 (15.5) – ≥ 3%, n (%) 104 (36.6) 88 (31.0) – 95 (33.5) 84 (29.6) – 98 (34.6) 79 (27.9) – HAQ-DI 1.2 (0.1) 1.4 (0.1) 0.03 1.1 (0.1) 1.3 (0.1) 0.003 1.1 (0.1) 1.3 (0.1) 0.002 PtGA, 0–100 58.3 (2.0) 63.2 (1.7) – 63.2 (1.9) 62.6 (1.8) – 61.0 (1.7) 60.9 (1.8) – PtGAJP, 0–100 54.9 (1.8) 57.4 (1.8) – 55.0 (1.9) 58.3 (1.8) – 55.0 (1.8) 56.5 (1.8) – SF-36 PCS 37.1 (0.7) 33.9 (0.7) 0.001 38.7 (0.7) 36.7 (0.7) 0.04 38.3 (0.7) 36.2 (0.8) – SF-36 MCS 45.6 (1.0) 44.7 (1.1) – 46.1 (1.0) 44.0 (1.1) – 45.3 (0.9) 47.5 (1.0) – Values are expressed as mean (SE) unless otherwise stated.
↵aP values are nominal.
↵bOnly P values ≥ 0.05 are shown. BSA: body surface area; CRP: C-reactive protein; ETN: etanercept; HAQ-DI, Health Assessment Questionnaire-Disability Index; MCS: Mental Component Summary; MTX: methotrexate; PCS: Physical Component Summary; PGA: physician global assessment; PsA: psoriatic arthritis; PtGA: patient global assessment of disease activity; PtGAJP: patient global assessment of joint pain; SE: standard error; SF-36: 36-item Short Form Health Survey; SJC66: swollen joint count in 66 joints; SPARCC: Spondyloarthritis Research Consortium of Canada; sPGA: static physician global assessment (of psoriasis); TJC68: tender joint count in 68 joints.
